期刊文献+

泰拉霉素中间体环氧化物的制备研究

Study on the Preparation of Epoxide Intermediate of Tulathromycin
下载PDF
导出
摘要 泰拉霉素是一种动物专用的大环内酯类半合成抗生素,国内已批准用于猪呼吸系统疾病的防治。而泰拉霉素酮化、环氧化合成工艺普遍存在收率低、副反应多、杂质高、纯化困难、不利于工业化生产等缺点,以去甲基阿奇霉素为原料,经三氟乙酸酐保护2’-位的羟基及6-位的氨基进行保护得到双保护去甲基阿奇霉素,Swern氧化将4″-位羟基氧化为羰基,再经硫叶立德环氧化得到泰拉霉素中间体环氧化物。双保护后不提纯,直接进行Swern氧化,工艺连续,简单可靠,收率高,所用原料廉价易得、绿色安全环保、工艺条件易于实现、副反应少,收率高,适于工业化生产。 Tulathromycin is a novel macrolide semisynthetic antibiotic for animals,which has been approved for use in the prevention and treatment of porcine respiratory disease in China.However,ketonic and epoxidized production of tulathromycin has some disadvantages such as low yield,a lot of side effects and impurities,difficult purification,and unconducive industrial production.In this paper,demethylazithromycin was used as raw material.The 2-hydroxyl group and 6-amino group protected by trifluoroacetic anhydride were used to produce the double-protected demethylazithromycin.The carbonyl group synthesized from 4-hydroxyl group using Swern-Oxidation was then epoxidized by sulfur Ylide to produce the intermediate epoxide of tulathromycin.Tulathromycin is synthesize by directly Swern-Oxidation,which does not need to be purified after double-protected pr process.This method has many advantages such as continuous,simple and reliable process,high yield,inexpensive and convenient raw materials,green,safe and environmentally friendly conditions,few side effects and suitable for industrial production.
作者 蒋宪龙 孔瑜 周立山 刘彩锋 刘海杰 Jiang Xianlong;Kong Yu;Zhou Lishan;Liu Caifeng;Liu Haijie(Xinfa Pharmaceutical Co.,Ltd.,Dongying 257500,China)
出处 《山东化工》 CAS 2024年第16期82-84,共3页 Shandong Chemical Industry
关键词 泰拉霉素 去甲基阿奇霉素 泰拉霉素中间体 环氧化物 tulathromycin demethylazithromycin tulathromycin intermediate epoxide
  • 相关文献

参考文献5

二级参考文献43

  • 1李玮,郭腾,陈洪亮,禚宝山.兽用新型大环内酯类抗生素——土拉霉素(ulathromycin)[J].中国动物保健,2006,8(4):38-39. 被引量:7
  • 2宋福杰,刘明春,邹美,符特.兽用抗菌药物土拉霉素研究进展[J].兽药与饲料添加剂,2006,11(4):4-6. 被引量:8
  • 3Benchaoui H A, Nowakowski M, Sherington J, et al. Pharmacokinetics and lung tissue concentrations of tulathromycin in swine [J].Veterinary Pharmacol and Therapeutics[J].2004,27(4):203-210. 被引量:1
  • 4FDA. Freedom of Information Summary NADAI41-244[Z]. Date of Approval:December 28,2007. 被引量:1
  • 5Orhan Sahin, Paul J. Plummer, et al. Emergence of a Tetracycline-resistant Campylobacter jejuni Clo Associated with Outbreaks of Ovine Abortion in th United States[J].Journal of clinical Microbiology 2008,46(5):1663-1671. 被引量:1
  • 6Godinho K S. Susceptibility testing of tulathromycin interpretative Breakpoints andsusceptibility of field isolates[J].Veterinary Microbiology. 2008, 129(3-4):426-432. 被引量:1
  • 7Nowakowski, Inskeep, et al. Pharmacokinetics and lung tissue concentrations of tulathromycin, a new triamilide antibiotic, In cattle[J].Veterinary Therapeutics, 2004,5(1):60-74. 被引量:1
  • 8Eberhard Scheuch, Janina Spieker, Monica Venner, et al Quantitative determination of the macrolide antibiotic tulathromycin in plasma and bronchoalveolar cells of foals using tandem mass spectrometry[J]. Journal of Chromatography B, 2007,850:464-470. 被引量:1
  • 9Committee for Veterinary Medicinal Products Tulathromycin, Summary Report(2).European Medicines Agency Veterinary Medicines and Inspections[Z].EMEA/MRL/ 894/04-Final. 2004. 被引量:1
  • 10Nutsch R G, Hart F J, Rooney K A. Efficacy of tulathromyein injectable solution for the treatment of naturally occurring Swine respiratory disease [J]. Veterinary Therapeutics. 2005,6(2):214-24. 被引量:1

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部